טוען...
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses
Previous studies have shown that during imatinib therapy, the decline of chronic myeloid leukaemia BCR-ABL transcript numbers involves a fast phase followed by a slow phase in averaged datasets. Drug resistance leads to regrowth. In this paper, variation of treatment responses between patients is ex...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Royal Society
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2871874/ https://ncbi.nlm.nih.gov/pubmed/20147328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1098/rspb.2009.2179 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|